biostudies-literatureEcsedi MFred Hutchinson Cancer Research CenterMPN Research FoundationNCI NIH HHSNIHDamon Runyon Cancer Research Foundation48-56https://www.ebi.ac.uk/biostudies/studies/S-EPMC7770096biostudies-literatureUnknown7(1)Adoptively transferred T cell receptor (TCR)-transgenic T cells (TCR-T cells) are not restricted by cell surface expression of their targets and are therefore poised to become a main pillar of cellular cancer immunotherapies. Addressing clinical and laboratory data, we discuss emerging features for the efficient deployment of novel TCR-T therapies, such as selection of ideal TCRs targeting validated epitopes with well-characterized cancer cell expression and processing, enhancing TCR-T effector function, trafficking, expansion, persistence, and memory formation by strategic selection of substrate cells, and gene-engineering with synthetic co-stimulatory circuits. Overall, a better understanding of the relevant mechanisms of action and resistance will help prioritize the vast array of potential TCR-T optimizations for future clinical products.Trends in cancerThe Anticancer Potential of T Cell Receptor-Engineered T Cells.PMC7770096CA18029-39P01 CA225517P01 CA018029CA225517-01McAfee MSEcsedi MChapuis AGfalseThe Anticancer Potential of T Cell Receptor-Engineered T Cells.Adoptively transferred T cell receptor (TCR)-transgenic T cells (TCR-T cells) are not restricted by cell surface expression of their targets and are therefore poised to become a main pillar of cellular cancer immunotherapies. Addressing clinical and laboratory data, we discuss emerging features for the efficient deployment of novel TCR-T therapies, such as selection of ideal TCRs targeting validated epitopes with well-characterized cancer cell expression and processing, enhancing TCR-T effector function, trafficking, expansion, persistence, and memory formation by strategic selection of substrate cells, and gene-engineering with synthetic co-stimulatory circuits. Overall, a better understanding of the relevant mechanisms of action and resistance will help prioritize the vast array of potential TCR-T optimizations for future clinical products.2021-01-01T00:00:00Z2021 Jan2025-04-04T13:12:18.154Z2022-02-11T14:02:12.52ZS-EPMC77700963298878710.1016/j.trecan.2020.09.002